Proteome Sciences PLC AGM Statement (6322X)
May 05 2021 - 6:00AM
UK Regulatory
TIDMPRM
RNS Number : 6322X
Proteome Sciences PLC
05 May 2021
5 May 2021
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Annual General Meeting (AGM) Statement
At the Company's AGM being held today at 11.00 am, the Chairman,
Christopher Pearce, will make the following statement:
"Having closed 2020 with a strong final quarter and order book
carried forward, we are pleased to report that the same pattern has
continued during the first quarter of 2021. We expect further
growth from the services business and TMT Pro(TM), assuming that
the general economic background continues to return more to
normality in the second half of 2021." Ends
For further information:
Proteome Sciences plc
Dr Mariola Soehngen, Chief Executive
Officer Tel: +44 (0)20 7043 2116
Dr Ian Pike, Chief Scientific Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMAAMLTMTIMMLB
(END) Dow Jones Newswires
May 05, 2021 06:00 ET (10:00 GMT)
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024